The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant cells displayed weak to moderate cytoplasmic staining with additional nuclear staining in some cases. A few cases of malignant glioma, adenocarcinoma, tumors of thyroid, cervical, urothelial and pancreas showed strong immunoreactivity.
A majority of malignant cells exhibited moderate cytoplasmic and/or nuclear immunoreactivity. Testicular cancers showed strong staining. A majority of ovarian, prostate, renal and liver cancers were negative.
Moderate cytoplasmic and nuclear immunoreactivity was observed in most malignant tissues. Colorectal and testicular cancers were strongly positive in several cases.
Malignant cells generally showed moderate cytoplasmic and membranous staining. Skin cancers displayed strong immunoreactivity in several cases.
Malignant cells showed cytoplasmic and nuclear positivity with varying intensity. Malignant melanomas and ovarian cancers exhibited strong immunoreactivity while several skin, breast and colorectal cancers were moderately positive. Most cases of malignant lymphomas, prostate, testicular and renal cancers were negative.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
